Trial · NCT04221451
Results by group96
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 96
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| PAP: PP: Percent Change From Baseline in CSF GM2 Biomarker to Week 104 | PAP: PP: Placebo | -11.33 | Standard Error 4.23 | percent change | |
| PAP: PP: Percent Change From Baseline in CSF GM2 Biomarker to Week 104 | PAP: PP: Venglustat | -47.57 | Standard Error 3.04 | percent change | |
| PAP: PP: Annualized Rate of Change From Baseline in the 9-HPT to Week 104 | PAP: PP: Placebo | 0.95 | Standard Error 1.92 | percent per year | |
| PAP: PP: Annualized Rate of Change From Baseline in the 9-HPT to Week 104 | PAP: PP: Venglustat | 2.49 | Standard Error 1.35 | percent per year | |
| PAP: SP: Percent Change From Baseline in Plasma and CSF Biomarkers (Glucosylceramide [GL-1] and GM2) to Week 104 in Juvenile/Adolescent Late-onset GM2 Gangliosidosis Participants | PAP: SP: Venglustat | GL-1: CSF | -82.35 | Standard Deviation 9.94 | percent change |
| PAP: SP: Percent Change From Baseline in Plasma and CSF Biomarkers (Glucosylceramide [GL-1] and GM2) to Week 104 in Juvenile/Adolescent Late-onset GM2 Gangliosidosis Participants | PAP: SP: Venglustat | GL-1: Plasma | -79.28 | Standard Deviation 2.56 | percent change |
| PAP: SP: Percent Change From Baseline in Plasma and CSF Biomarkers (Glucosylceramide [GL-1] and GM2) to Week 104 in Juvenile/Adolescent Late-onset GM2 Gangliosidosis Participants | PAP: SP: Venglustat | GM2: CSF | -43.41 | Standard Deviation 23.14 | percent change |
| PAP: SP: Percent Change From Baseline in Plasma and CSF Biomarkers (Glucosylceramide [GL-1] and GM2) to Week 104 in Juvenile/Adolescent Late-onset GM2 Gangliosidosis Participants | PAP: SP: Venglustat | GM2: Plasma | -55.91 | Standard Deviation 11.76 | percent change |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1 and GM1 Biomarkers to Week 104 in GM1 Gangliosidosis Participants | PAP: SP: Venglustat | GL-1: CSF | 17.42 | Standard Deviation 188.41 | percent change |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1 and GM1 Biomarkers to Week 104 in GM1 Gangliosidosis Participants | PAP: SP: Venglustat | GL-1: Plasma | -80.42 | Standard Deviation 8.17 | percent change |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1 and GM1 Biomarkers to Week 104 in GM1 Gangliosidosis Participants | PAP: SP: Venglustat | GM1: CSF | -32.35 | Standard Deviation 17.46 | percent change |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1 and GM1 Biomarkers to Week 104 in GM1 Gangliosidosis Participants | PAP: SP: Venglustat | GM1: Plasma | -52.32 | Standard Deviation 16.76 | percent change |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM2 and Monosialodihexosylganglioside (GM3) Biomarkers to Week 104 in Sialidosis Type 1 Participant | PAP: SP: Venglustat | GL-1: CSF | NA | percent change | |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM2 and Monosialodihexosylganglioside (GM3) Biomarkers to Week 104 in Sialidosis Type 1 Participant | PAP: SP: Venglustat | GL-1: Plasma | NA | percent change | |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM2 and Monosialodihexosylganglioside (GM3) Biomarkers to Week 104 in Sialidosis Type 1 Participant | PAP: SP: Venglustat | GM2: CSF | NA | percent change | |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM2 and Monosialodihexosylganglioside (GM3) Biomarkers to Week 104 in Sialidosis Type 1 Participant | PAP: SP: Venglustat | GM2: Plasma | NA | percent change | |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM2 and Monosialodihexosylganglioside (GM3) Biomarkers to Week 104 in Sialidosis Type 1 Participant | PAP: SP: Venglustat | GM3: CSF | NA | percent change | |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM2 and Monosialodihexosylganglioside (GM3) Biomarkers to Week 104 in Sialidosis Type 1 Participant | PAP: SP: Venglustat | GM3: Plasma | NA | percent change | |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM1 and GM3 Biomarkers to Week 104 in Juvenile/Adult Galactosialidosis Participants | PAP: SP: Venglustat | GL-1: CSF | NA | percent change | |
| PAP: SP: Percent Change From Baseline in Plasma and CSF GL-1, GM1 and GM3 Biomarkers to Week 104 in Juvenile/Adult Galactosialidosis Participants | PAP: SP: Venglustat | GL-1: Plasma | NA | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04221451/results